Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F7 | P08709 | 2/20 | 0.66 |
| ▸ | F3 | P13726 | 2/20 | 0.66 |
| ▸ | CNR1 | P21554 | 2/20 | 0.61 |
| ▸ | CNR2 | P34972 | 2/20 | 0.61 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.61 |
| ▸ | TERT | O14746 | 3/20 | 0.60 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.60 |
| ▸ | PPARG | P37231 | 3/20 | 0.60 |
| ▸ | PPARD | Q03181 | 3/20 | 0.60 |
| ▸ | PPARA | Q07869 | 3/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.60 |
| ▸ | MAPT | P10636 | 2/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.60 |
| ▸ | BLM | P54132 | 2/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.60 |
| ▸ | FABP4 | P15090 | 2/20 | 0.60 |
| ▸ | FAAH | O00519 | 2/20 | 0.60 |
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | GMNN | O75496 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2703278 | 0.96 | TERT (0.66) | F7F3TERTPTPN1PPARG | |
| SCHEMBL540383 | 0.96 | TERT (0.66) | F7F3TERTPTPN1PPARG | |
| SCHEMBL2788686 | 0.96 | TERT (0.66) | F7F3TERTPTPN1PPARG | |
| SCHEMBL422846 | 0.96 | TERT (0.66) | F7F3TERTPTPN1PPARG | |
| SCHEMBL5077835 | 0.96 | TERT (0.66) | F7F3TERTPTPN1PPARG | |
| SCHEMBL8150267 | 0.96 | TERT (0.66) | F7F3TERTPTPN1PPARG | |
| SCHEMBL4188223 | 0.96 | TERT (0.66) | F7F3TERTPTPN1PPARG | |
| SCHEMBL424098 | 0.96 | TERT (0.66) | F7F3TERTPTPN1PPARG | |
| SCHEMBL10488884 | 0.96 | TERT (0.66) | F7F3TERTPTPN1PPARG | |
| SCHEMBL9517250 | 0.96 | TERT (0.66) | F7F3TERTPTPN1PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9226925-B1 | Abuse deterrent and anti-dose dumping pharmaceutical salts useful for the treatment of attention deficit/hyperactivity disorder | PISGAH LABORATORIES, INC. (US) | 2016-01-05 | — | — | US | claimed |
| US-8940729-B1 | Abuse deterrent and anti-dose dumping pharmaceutical salts useful for the treatment of attention deficit/hyperactivity disorder | PISGAH LABORATORIES, INC. (US) | 2015-01-27 | — | — | US | claimed |
| US-8912217-B1 | Abuse deterrent and anti-dose dumping pharmaceutical salts useful for the treatment of attention deficit/hyperactivity disorder | PISGAH LABORATORIES, INC. (US) | 2014-12-16 | — | — | US | claimed |
| US-9226925-B1 | Abuse deterrent and anti-dose dumping pharmaceutical salts useful for the treatment of attention deficit/hyperactivity disorder | PISGAH LABORATORIES, INC. (US) | 2016-01-05 | — | — | US | disclosed |
| US-8980880-B1 | Abuse deterrent and anti-dose dumping pharmaceutical salts useful for the treatment of attention deficit/hyperactivity disorder | PISGAH LABORATORIES, INC. (US) | 2015-03-17 | — | — | US | disclosed |
| US-8957067-B1 | Abuse deterrent and anti-dose dumping pharmaceutical salts useful for the treatment of attention deficit/hyperactivity disorder | PISGAH LABORATORIES, INC. (US) | 2015-02-17 | — | — | US | disclosed |
| US-8940729-B1 | Abuse deterrent and anti-dose dumping pharmaceutical salts useful for the treatment of attention deficit/hyperactivity disorder | PISGAH LABORATORIES, INC. (US) | 2015-01-27 | — | — | US | disclosed |
| US-8916587-B1 | Abuse deterrent and anti-dose dumping pharmaceutical salts useful for the treatment of attention deficit/hyperactivity disorder | PISGAH LABORATORIES, INC. (US) | 2014-12-23 | — | — | US | disclosed |
| US-8912217-B1 | Abuse deterrent and anti-dose dumping pharmaceutical salts useful for the treatment of attention deficit/hyperactivity disorder | PISGAH LABORATORIES, INC. (US) | 2014-12-16 | — | — | US | disclosed |
| US-8846766-B2 | Abuse-deterrent methadone for the safe treatment of drug abuse and pain relief | PISGAH LABORATORIES, INC. (US) | 2014-09-30 | — | — | US | disclosed |
| US-8716278-B1 | Abuse deterrent and anti-dose dumping pharmaceutical salts useful for the treatment of attention deficit/hyperactivity disorder | PISGAH LABORATORIES, INC. (US) | 2014-05-06 | — | — | US | disclosed |
| US-8716337-B1 | Abuse deterrent and anti-dose dumping pharmaceutical salts useful for the treatment of attention deficit/hyperactivity disorder | PISGAH LABORATORIES, INC. (US) | 2014-05-06 | — | — | US | disclosed |
| US-8653106-B2 | Abuse deterrent and anti-dose dumping pharmaceutical salts useful for the treatment of attention deficit/hyperactivity disorder | PISGAH LABORATORIES, INC. (US) | 2014-02-18 | — | — | US | disclosed |
| US-8653065-B1 | Abuse deterrent and anti-dose dumping pharmaceutical salts useful for the treatment of attention deficit/hyperactivity disorder | PISGAH LABORATORIES, INC. (US) | 2014-02-18 | — | — | US | disclosed |
| US-20130338229-A1 | Abuse-Deterrent Methadone for the Safe Treatment of Drug Abuse and Pain Relief | Pisgah National Laboratories, Inc. (US) | 2013-12-19 | — | — | US | disclosed |
| US-8586575-B1 | Abuse deterrent and anti-dose dumping pharmaceutical salts useful for the treatment of attention deficit/hyperactivity disorder | PISGAH LABORATORIES, INC. (US) | 2013-11-19 | — | — | US | disclosed |
| US-20120028960-A1 | ABUSE DETERRENT AND ANTI-DOSE DUMPING PHARMACEUTICAL SALTS USEFUL FOR THE TREATMENT OF ATTENTION DEFICIT/HYPERACTIVITY DISORDER | PISGAH LABORATORIES, INC. | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130338229-A1 | Abuse-Deterrent Methadone for the Safe Treatment of Drug Abuse and Pain Relief | OPRM1, OGFR, OPRK1 | F7 2920/4885F3 3819/4885CNR1 432/4885 |
| US-20120028960-A1 | ABUSE DETERRENT AND ANTI-DOSE DUMPING PHARMACEUTICAL SALTS USEFUL FOR THE TREATMENT OF ATTENTION DEFICIT/HYPERACTIVITY DISORDER | COMT, SLC6A3, SLC6A2 | F7 3502/4885F3 4155/4885CNR1 1799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.